Paul K. Paik

Oncology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 94 publications

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 08, 2026

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2026

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2026

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Journal: JCO precision oncology
Published: December 05, 2025

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Journal: Nature medicine
Published: November 20, 2025

Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options.

Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options.

Journal: Clinical lung cancer
Published: May 01, 2025

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer.

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer.

Journal: Cancer treatment reviews
Published: May 01, 2025

Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry.

Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 26, 2025

Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 08, 2025

Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.

Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 13, 2024

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping.

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping.

Journal: Cancer
Published: August 13, 2024

Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.

Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.

Journal: ESMO open
Published: August 01, 2024
Showing 1-12 of 94

Last Updated: 09/26/2026